RSS Feeds
Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension
- David B. Matchar, MD;
- Douglas C. McCrory, MD, MHS;
- Lori A. Orlando, MD, MHS;
- Manesh R. Patel, MD;
- Uptal D. Patel, MD;
- Meenal B. Patwardhan, MD, MHSA;
- Benjamin Powers, MD;
- Gregory P. Samsa, PhD; and
- Rebecca N. Gray, DPhil
- From Duke Center for Clinical Health Policy Research, Duke Clinical Research Institute, Duke University, and the Center for Health Services Research in Primary Care, Durham U.S. Department of Veterans Affairs Medical Center, Durham, North Carolina.
-
Figure 1. Study flow diagram.*See Appendix 1. ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker.
-
Figure 2. Successful monotherapy: angiotensin-converting enzyme (ACE) inhibitors versus angiotensin II receptor blockers (ARBs).The first group is observational studies and the second group is randomized, controlled trials.
-
Figure 3. Cough as an adverse event: angiotensin-converting enzyme (ACE) inhibitors versus angiotensin II receptor blockers (ARBs).The first group is observational studies and the second group is randomized, controlled trials.
-
Figure 4. Withdrawals due to adverse events: angiotensin-converting enzyme (ACE) inhibitors versus angiotensin II receptor blockers (ARBs).The first group is observational studies and the second group is randomized, controlled trials.
Related Clinical Content
